According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment Landscape Across Tumor Types
Oncologists, surgeons, and specialists surveyed cite long-term survival, prevention of relapse or recurrence and quality of life as most important factors when making treatment decisions before and/or after surgery
“Cancer recurrence often marks the transition from curable to incurable disease and can be life-altering for patients, which is why we continually investigate ways to improve upon the standard of care,” said
Current Treatment Approaches in Earlier Stages of Cancer
Today, treatment in the neoadjuvant, adjuvant or peri-operative settings may consist of chemotherapy, radiation, targeted therapy, chemoradiation therapy, and increasingly in a subset of tumors, immunotherapy. The survey identified a number of trends on the current use, satisfaction and drivers of treatment choices in earlier-stage cancers.
- HCPs surveyed do not always use treatment beyond surgery: The majority of HCPs surveyed report that they “sometimes” use neoadjuvant (62%), adjuvant (55%) or peri-operative (54%) treatments for patients with earlier stages of cancer, highlighting the opportunity for earlier intervention.
- HCPs surveyed are more satisfied with current treatments in cancers where earlier options are well established : Six out of 10 or more survey respondents are “very” or “fairly” satisfied with current neoadjuvant (67%), adjuvant (70%) and peri-operative (61%) treatment options as a whole. However, satisfaction varies by tumor* and is highest among cancers with well-established therapies, like breast cancer (87% satisfaction in the neoadjuvant/adjuvant settings) and melanoma (77% satisfaction in adjuvant). In kidney and liver cancers, satisfaction is noticeably lower (less than 35% satisfaction with neoadjuvant, adjuvant and peri-operative options), signaling the need for additional research.
- HCPs surveyed use immunotherapy in earlier stages (either as approved therapies or in clinical trials), but not as often as other treatments : Currently, respondents report more experience using chemotherapy (85%, 86% and 73% for neoadjuvant, adjuvant and peri-operative, respectively) than immunotherapy (48%, 65% and 39%, respectively), likely reflecting that immunotherapy remains under investigation in a number of tumor types and only recently emerged as an approved option in others.
The Potential of Immunotherapy for the Future of Earlier-Stage Treatment
To better understand the future landscape of neoadjuvant, adjuvant and peri-operative treatment, the survey explored HCPs’ perceptions of immunotherapy and found:
- Many HCPs surveyed see potential for a positive impact with immunotherapy in earlier stages of disease: Participants see the greatest potential for positive outcomes in melanoma (92% report positive potential impact in the adjuvant setting), lung cancer (89% in the neoadjuvant setting) and bladder or urothelial cancer (84% in the adjuvant setting).*
- HCPs surveyed believe the potential benefits of immunotherapy align with what currently drives treatment preferences in earlier settings : Selecting from a list, HCPs surveyed state the most important potential benefits of immunotherapy as longer overall survival (64%), increased disease-free, event-free or recurrence-free survival (57%) and maintenance of quality of life (54%). These responses align with the factors HCPs surveyed report as most important in making treatment decisions in patients with operable tumors (long-term survival, prevention of relapse or recurrence and quality of life).
- HCPs surveyed cite the need for more data as a leading barrier to adoption of immunotherapy in earlier stages of cancer : From a list, surveyed participants selected the need for long-term and overall survival data as leading barriers to adoption of immunotherapy in earlier stages of cancer (53% and 50%, respectively), reinforcing the importance of ongoing research and follow-up analyses.
“Over the past decade, immunotherapy research has evolved, starting with a focus on metastatic cancers, and more recently, expanding to explore the role of these treatments in earlier stages of the disease,” said
*Tumor-specific results are based on responses from HCPs who currently treat these types of cancer, a subset of the full sample.
About the Survey
On behalf of
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended